Background: Limitations of Unidirectional Immune Cell Analysis and Bottlenecks in the R&D of Refractory B-Cell Lymphoma: Clonal Evolution and Immune Evasion Data

Conventional standard guidelines, centered on single immune phenotype separation and bulk transcriptomic profiling, fail to control noise arising from the disruption of cellular heterogeneity within the highly dynamic tumor microenvironment. This also creates critical blind spots in elucidating the reversible state changes of intracellular metabolic flux in response to T-cell receptor activation at the in silico level. In particular, antigen escape and the evolution of the tumor microenvironment into an immunosuppressive state, observed after the administration of approved CD19-targeted chimeric antigen receptor (CAR) therapies such as Novartis's Tisagenlecleucel and Gilead/Kite's Axicabtagene ciloleucel, have posed a critical data barrier that hinders long-term engraftment after initial remission. Technical variations and batch effects in patient-derived omics data have severely limited the determination of immune cell effective lifespan through signaling behavior and free energy of binding calculations, resulting in a persistent genomic information bottleneck in the development of new drug pipelines that fail to proactively maintain the optimal active engraftment concentration for long-term follow-up and clinical cure.

Discovery: Implementation of Geometry-Based Deep Learning Receptor Tensor Synchronization and Demonstration of Single-Cell Resolution Immune-Tumor Interaction Topological Curves

In this study, we implemented a multi-omic tensor synchronization algorithm that integrates single-cell RNA-seq and T-cell receptor repertoire matrices to successfully and precisely predict in silico the free energy landscape of the docking interface formed when CAR T-cells contact target cells within the tumor microenvironment, as well as the differential equation-based rate constants. By implementing a single-cell multi-omics batch effect removal protocol that disruptively surpasses simple linear correction of existing statistical models, we completely eliminated inter-donor biological variations and elucidated the topological variation curves of downstream transcriptomic networks at the spatial resolution scale during synapse formation. Analysis of long-term follow-up cohort clinical data (NEJMoa2518035, 2026), spanning a decade, demonstrated the molecular integrity that ensures sustained in vivo self-renewal and permanent anti-tumor surveillance activity by tracing back from the gene expression gradient to prevent immune cell exhaustion and induce memory T-cell subtypes.

Establishment of a Precision-Layered Model for Tuning Chimeric Antigen Receptor Dynamics and Reversible Immune Homeostasis

Within the constructed computational architecture, the omics matrix maps the genetic variations of patient-specific cancers in a high-dimensional manner, driving a precision stratification algorithm based on patient molecular phenotypes and pre-filtering the false-positive spectrum of severe immune-related adverse events, such as cytokine release syndrome and neurotoxicity, that may be induced after drug administration. By up- and down-regulating the rate-limiting step constants of the cell death pathway at the molecular level, we prevent damage to normal cells and extend effective immune lifespan, and by incorporating the immune-active landscape of long-term survivors into a feedback loop, we induce autonomous preservation of immune homeostasis even under aberrant tumor heterogeneity. This precision stratification backbone model moves beyond existing treatment scenarios that are fixed on a single genetic gradient, providing a framework for pre-simulating patient-specific genetic backgrounds and enabling the spontaneous restoration of homeostasis in long-term immune surveillance cell populations.

Prospects: Establishment of a Standard for Programmable Cancer Immunotherapy and Implementation of Next-Generation IND Digital Governance

This computational biology architecture resets the classical post-hoc, descriptive analysis system into a programmable cancer immune control infrastructure based on multi-dimensional genomic tensor modeling, and will be established as a core computational asset that accelerates the development of next-generation multi-target cell therapy pipelines for multinational pharmaceutical companies. By linking genetic gradient correction coefficients in real-time to the large-scale sequencing flow accumulated during the high-throughput screening phase, we can eliminate inter-batch heterogeneity in cGMP manufacturing processes and secure a robust technological barrier that eliminates clinical variations in treatment efficacy. Ultimately, we aim to fully meet the companion diagnostic (CDx) technology specifications of global regulatory agencies such as the U.S. FDA, and to establish a governance approval framework that allows for the submission of digital modeling data to replace the non-clinical efficacy demonstration section of new drug investigational new drug (IND) applications, thereby disruptively shortening the regulatory approval timeline.